SPOTLIGHT -
EP. 1: Introduction: Expanded RAS Testing in Colorectal Cancer
EP. 2: Optimizing Treatment With EGFR Inhibitors in CRC
EP. 3: Clinical Development of Cetuximab in mCRC
EP. 4: Upfront Bevacizumab and Cetuximab Compared in mCRC
EP. 5: Treatment of Unresectable RAS Wild-type Metastatic CRC
EP. 6: First- and Later-line Use of Panitumumab in mCRC
EP. 7: Considerations When Selecting an EGFR Inhibitor in mCRC
EP. 8: Role of the Multikinase Inhibitor Regorafenib in mCRC
EP. 9: Role of the VEGF Inhibitor Aflibercept in mCRC
EP. 10: New Therapies in Development for mCRC
EP. 11: Tumor Profiling in Patients With mCRC
EP. 12: Current Trends in the Treatment of CRC
EP. 13: First- and Second-Line Treatment of mCRC in Specific Populations
EP. 14: Third-Line Treatment Options for mCRC
EP. 15: Panitumumab, Regorafenib, and Ziv-aflibercept in mCRC
EP. 16: Final Thoughts on the Treatment of mCRC
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
